FMP
Liminal BioSciences Inc.
LMNL
NASDAQ
Inactive Equity
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
8.5 USD
0.01 (0.118%)
2022
2021
2020
2019
401k
643k
3.32M
4.9M
0
0
2.03M
2.76M
401k
643k
1.28M
2.14M
33.16M
50.27M
95.38M
120.4M
15.3M
18.35M
56.83M
75.11M
17.87M
31.93M
38.55M
45.28M
0
0
0
0
0
0
0
0
-212k
75k
79k
-92.37M
-32.98M
-49.56M
-94.27M
-210.63M
-525k
118k
-28.07M
-237k
-29.44M
-44.95M
-122.34M
-234.46M
-525k
118k
-201k
-237k
-28.92M
-45.06M
-122.14M
-234.22M
-9.32
-14.94
-49.97
-145.82
-9.32
-14.94
-49.97
-145.82
3.1M
3.02M
2.44M
1.61M
3.1M
3.02M
2.44M
1.61M
-31.86M
-45.21M
-85.83M
-200.72M
2022
2021
2020
2019
-1.07B
-1.09B
-967.05M
-755.69M
-28.92M
-45.06M
-122.14M
-234.22M
0
0
0
0
0
0
0
0
-1.08B
-1.07B
-1.09B
-967.05M
-8.13M
12.88M
-120M
-211.36M
2022
2021
2020
2019
5.49M
7.09M
27.35M
54.73M
1.12M
4.34M
8.45M
9.91M
-19k
-463k
-2.05M
-4.44M
4.39M
3.21M
20.95M
49.26M
2022
2021
2020
2019
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in CAD.